Abstract | BACKGROUND: METHODS: RESULTS:
VEGF was expressed in 100% of vestibular schwannomas and VEGFR-2 in 32% of tumor vessels on immunohistochemical analysis. Before treatment, the median annual volumetric growth rate for 10 index tumors was 62%. After bevacizumab treatment in the 10 patients, tumors shrank in 9 patients, and 6 patients had an imaging response, which was maintained in 4 patients during 11 to 16 months of follow-up. The median best response to treatment was a volumetric reduction of 26%. Three patients were not eligible for a hearing response; of the remaining seven patients, four had a hearing response, two had stable hearing, and one had progressive hearing loss. There were 21 adverse events of grade 1 or 2. CONCLUSIONS:
|
Authors | Scott R Plotkin, Anat O Stemmer-Rachamimov, Fred G Barker 2nd, Chris Halpin, Timothy P Padera, Alex Tyrrell, A Gregory Sorensen, Rakesh K Jain, Emmanuelle di Tomaso |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 361
Issue 4
Pg. 358-67
(Jul 23 2009)
ISSN: 1533-4406 [Electronic] United States |
PMID | 19587327
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | 2009 Massachusetts Medical Society |
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Neuropilin-2
- Vascular Endothelial Growth Factor A
- Neuropilin-1
- Bevacizumab
- Vascular Endothelial Growth Factor Receptor-2
|
Topics |
- Adolescent
- Adult
- Angiogenesis Inhibitors
(adverse effects, therapeutic use)
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Female
- Hearing Loss
(drug therapy, etiology)
- Humans
- Male
- Middle Aged
- Neurofibromatosis 2
(complications)
- Neuroma, Acoustic
(complications, drug therapy, metabolism)
- Neuropilin-1
(metabolism)
- Neuropilin-2
(metabolism)
- Retrospective Studies
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors, metabolism)
- Vascular Endothelial Growth Factor Receptor-2
(metabolism)
- Young Adult
|